In Partnership With:
Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.
Revisit Every OncLive On Air Episode From April 2024
Revisit the OncLive On Air Episodes From February 2024
Ongoing Research Aims to Expand Treatment Options, Address Unmet Needs in GVHD
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward
Which JAK Inhibitor in Myelofibrosis: Deciding Factors in Treatment Selection
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer
Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer
Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC
Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer